GlassScriptPhysician profile
Cybele C Woon
NPI 1487738878
$5,490.98
in general payments reported to CMS, 2019-2025
27 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $873 · 2021: $850 · 2022: $420 · 2023: $988 · 2024: $1,301 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.03 | 2022-2025 | Lumigan, Botox, Vuity |
| Merz North America, INC. | $627.32 | 2019-2024 | |
| Glaukos Corporation | $445.84 | 2021-2024 | Ce-Marked Kxla System |
| Alexion Pharmaceuticals, INC. | $394.86 | 2019-2025 | Ultomiris |
| Allergan, INC. | $394.45 | 2019-2022 | |
| Ucb, INC. | $386.79 | 2023-2025 | Rystiggo |
| Alcon Vision LLC | $330.92 | 2021-2024 | Clareon, Argos, Rocklatan |
| Sun Pharmaceutical Industries INC. | $296.08 | 2019-2024 | |
| Kala Pharmaceuticals, INC. | $230.58 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $195.89 | 2019-2021 | |
| Horizon Therapeutics Plc | $159.44 | 2021-2023 | Uplizna |
| Tarsus Pharmaceuticals, INC. | $150.88 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $139.73 | 2020-2021 | |
| Amgen INC. | $126.43 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $89.60 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $87.67 | 2022-2025 | Vyzulta |
| Dompe US, INC. | $85.65 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $70.18 | 2019-2022 | |
| Revance Therapeutics, INC. | $65.72 | 2024 | Daxxify |
| Oyster Point Pharma, INC. | $61.97 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $60.15 | 2024-2025 | Vevye |
| Argenx US, INC. | $56.27 | 2023 | Vyvgart |
| Thea Pharma INC. | $45.03 | 2023-2024 | Iyuzeh |
| Catalyst Pharmaceuticals, INC. | $32.22 | 2024 | |
| Mallinckrodt Enterprises LLC | $23.29 | 2019 | |
| Rxsight INC | $23.19 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cybele Woon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.